We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
New molecular entity: Treanda.
- Abstract
The article reports on the approval given to bendamustine, an alkylating agent, from Cephalon Inc. by the U.S. Food and Drug Administration. The drug was approved on March 20, 2008 for the treatment of chronic lymphocytic leukemia (CLL). The efficacy of bendamustine was evaluated in a multicenter trial to treat Binet stage B or C CLL and its treatment is associated with myelosuppression. Its recommended dose is 100 milligrams administered as an intravenous infusion over 30 minutes.
- Subjects
UNITED States; DRUG approval; ALKYLATING agents; CEPHALON Inc.; CHRONIC lymphocytic leukemia; DRUG efficacy; DRUG dosage; UNITED States. Food &; Drug Administration
- Publication
Formulary, 2008, Vol 43, Issue 5, p156
- ISSN
1082-801X
- Publication type
Article